36
Participants
Start Date
August 31, 2007
Primary Completion Date
January 31, 2010
Study Completion Date
February 28, 2010
SGN-40
2-12 mg/kg IV (in the vein) on Days 1, 4, 8, 15, and 22 of Cycle 1; 4-12 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 of Cycles 2-4; 4-12 mg/kg IV (in the vein) on Days 1, 8, and 15 of Cycles 5-8.
lenalidomide
Up to 25 mg daily of a 21-day cycle.
dexamethasone
40 mg administered weekly.
Weill Medical College of Cornell University, New York
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Barbara Ann Karmanos Cancer Institute, Detroit
Avera Cancer Institute, Sioux Falls
Nebraska Methodist Hospital, Omaha
Baylor University Medical Center, Dallas
Rocky Mountain Cancer Center, Denver
Dana Farber Cancer Institute, Boston
Hackensack University Medical Center, Hackensack
Collaborators (1)
Genentech, Inc.
INDUSTRY
Seagen Inc.
INDUSTRY